A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH

Autores
Categoria Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
Besides the main objectives, there are other objectives as follows: 1. To evaluate efficacy of ALS-L1023 for liver fibrosis and steatosis by noninvasive imaging biomarker MRI-PDFF and MRE 2. To determine optimized dose of ALS-L1023 in NASH disease
Epistemonikos ID: 6f81c4bad57dcb0e5e1fe44d9096df4df5afabbb
First added on: May 07, 2024